Publication

EULAR •
13 June, 2025 •
•

Exposure–safety analysis from two clinical trials of emapalumab in patients with macrophage activation syndrome in Still’s disease

Rafael T. Krmar, Brian Jamieson, Kristina Star, Anna Stoltenberg, Adnan Mahmood, Uwe Ullmann, Fabrizio De Benedetti, Alexei A. Grom,, Axel Facius, Patrick Brossard

Available materials

Poster

Publication

EULAR •
13 June, 2025 •
•

Efficacy and Safety of Emapalumab in Patients with Macrophage Activation Syndrome in Still’s disease: Results from a Pooled Analysis of Two Prospective Trials

Alexei Grom, Uwe Ullmann, Adnan Mahmood, Josefin Blomkvist, Brian Jamieson, Fabrizio De Benedetti

Available materials

Oral Presentation

Symposium

EULAR •
13 June, 2025 •
•

Putting on your VEXAS goggles: Seeing what’s in plain sight

Sophie Georgin-Lavialle, Thibault Mahevas, Lachelle D. Weeks, Sara Bindoli

Available materials

Slides Video

Publication

Variations in Chronic Refractory Gout Management between Rheumatologists and Nephrologists

Exposure–safety analysis from two clinical trials of emapalumab in patients with macrophage activation syndrome in Still’s disease

Efficacy and Safety of Emapalumab in Patients with Macrophage Activation Syndrome in Still’s disease: Results from a Pooled Analysis of Two Prospective Trials

Putting on your VEXAS goggles: Seeing what’s in plain sight

Association Between Clinical Manifestations of Gout and Patient Reported Outcome Measures: Results of a Real-World Survey in the United States

Nanoencapsulated Sirolimus Plus Pegadricase (NASP) Provides a Sustained 48-Week Response, Reducing Serum Uric Acid and Preserving Renal Function in Patients With Uncontrolled Gout (UG) and Stage 3 Chronic Kidney Disease

Treatment Patterns and Clinical Outcomes in Patients with both Uncontrolled Gout and Chronic Kidney Disease

Comparison of Diagnostic Journey and Utilization of Clinical Care Resources in Uncontrolled vs. Controlled Gout in the United States

Variations in Chronic Refractory Gout Management between Rheumatologists and Nephrologists

Exposure–safety analysis from two clinical trials of emapalumab in patients with macrophage activation syndrome in Still’s disease

Efficacy and Safety of Emapalumab in Patients with Macrophage Activation Syndrome in Still’s disease: Results from a Pooled Analysis of Two Prospective Trials

Putting on your VEXAS goggles: Seeing what’s in plain sight​

Association Between Clinical Manifestations of Gout and Patient Reported Outcome Measures: Results of a Real-World Survey in the United States

Nanoencapsulated Sirolimus Plus Pegadricase (NASP) Provides a Sustained 48-Week Response, Reducing Serum Uric Acid and Preserving Renal Function in Patients With Uncontrolled Gout (UG) and Stage 3 Chronic Kidney Disease

Treatment Patterns and Clinical Outcomes in Patients with both Uncontrolled Gout and Chronic Kidney Disease

Comparison of Diagnostic Journey and Utilization of Clinical Care Resources in Uncontrolled vs. Controlled Gout in the United States

Putting on your VEXAS goggles: Seeing what’s in plain sight